Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792682 | 0.89 | PARP10 (0.35) | — | |
| SCHEMBL25590825 | 0.86 | SRC (0.35) | SRCTRPV1MEN1CYP1A2CRHBP | |
| SCHEMBL20904391 | 0.81 | SRC (0.34) | SRCTRPV1 | |
| SCHEMBL10912802 | 0.79 | SRC (0.46) | SRCCASP1CASP7 | |
| SCHEMBL19511770 | 0.74 | SRC (0.46) | SRCMEN1CASP1CASP7KMT2A | |
| SCHEMBL4567533 | 0.72 | GRIA1 (0.41) | TRPV1CASP1CASP7 | |
| SCHEMBL19103015 | 0.72 | SRC (0.41) | SRC | |
| SCHEMBL22389361 | 0.72 | GAA (0.33) | SRCMEN1CYP1A2CRHBPCASP1 | |
| SCHEMBL3744568 | 0.71 | SRC (0.38) | SRCMEN1CASP1CASP7KMT2A | |
| SCHEMBL20904541 | 0.70 | SRC (0.31) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7956064-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110112086-A1 | PYRIDINONE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7910600-B2 | Therapeutic kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | SENHWA BIOSCIENCES, INC. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20100305136-A1 | QUINOLONE ANALOGS DERIVATIZED WITH SULFONIC ACID, SULFONATE OR SULFONAMIDE | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-02 | — | — | US | disclosed |
| US-7834180-B2 | Methods of preparing quinolone analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7816524-B2 | Methods of preparing quinolone analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20080318939-A1 | METHODS FOR TREATING OPHTHALMIC DISORDERS | CYLENE PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318938-A1 | METHODS FOR TREATING ABERRANT CELL PROLIFERATION DISORDERS | CYLENE PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080261963-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-7402579-B2 | Quinobenzoxazine analogs and compositions | CYLENE PHARMACEUTICALS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7381720-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7354916-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS (US) | 2008-04-08 | — | — | US | disclosed |
| US-7326702-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070117770-A1 | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof | CYLENE PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070032652-A1 | Methods of preparing quinolone analogs | SENHWA BIOSCIENCES, INC. (TW) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PARP1, PARP11, TNKS | SRC 478/4885TRPV1 3730/4885MEN1 3970/4885 |
| US-20080318939-A1 | METHODS FOR TREATING OPHTHALMIC DISORDERS | EYA3, UACA, ALDH1A2 | SRC 4163/4885TRPV1 884/4885MEN1 743/4885 |
| US-20080261963-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYP3A5, UGT2B7, CYP2D6 | SRC 1563/4885TRPV1 1659/4885MEN1 3714/4885 |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYP3A5, UGT2B7, CYP2D6 | SRC 1563/4885TRPV1 1659/4885MEN1 3714/4885 |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | TP53, CCNY, ACIN1 | SRC 702/4885TRPV1 4120/4885MEN1 3189/4885 |
| US-20080318938-A1 | METHODS FOR TREATING ABERRANT CELL PROLIFERATION DISORDERS | MKI67, PCNA, CCNC | SRC 812/4885TRPV1 4820/4885MEN1 1454/4885 |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | EIF2AK2, DDX21, POLI | SRC 4460/4885TRPV1 3700/4885MEN1 2881/4885 |
| US-20100305136-A1 | QUINOLONE ANALOGS DERIVATIZED WITH SULFONIC ACID, SULFONATE OR SULFONAMIDE | NQO2, STS, SQOR | SRC 2626/4885TRPV1 3661/4885MEN1 3586/4885 |
| US-20110112086-A1 | PYRIDINONE ANALOGS | API5, BAD, PDXK | SRC 3448/4885TRPV1 4301/4885MEN1 2464/4885 |
| US-20070032652-A1 | Methods of preparing quinolone analogs | BAX, BAD, MCL1 | SRC 3953/4885TRPV1 4805/4885MEN1 2224/4885 |
| US-20070117770-A1 | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof | NOP2, POLRMT, FBL | SRC 3022/4885TRPV1 4802/4885MEN1 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.